Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 23, 2017 ) Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver which leads to cirrhosis. Symptoms of NASH include fatigue weight loss for no clear reason general weakness and an ache in the upper right part of belly. Risk factors include obesity type 2 diabetes high cholesterol and high triglycerides and metabolic syndrome.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I IND/CTA Filed Preclinical Discovery and Unknown stages are 6 28 27 3 75 28 and 2 respectively. Similarly the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules respectively.
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/non-alcoholic-steatohepatitis-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) . - The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881449/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles AdAlta Ltd Albireo Pharma Inc Allergan Plc Alnylam Pharmaceuticals Inc Amunix Operating Inc Aquinox Pharmaceuticals Inc Arcturus Therapeutics Inc Ardelyx Inc AstraZeneca Plc Betagenon AB BioLineRx Ltd Bird Rock Bio Inc BLR Bio LLC
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881449/discount
List of Tables Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH) H2 2017 Number of Products under Development by Companies H2 2017 Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017 Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017 Number of Products under Development by Companies H2 2017 (Contd..3) H2 2017 Number of Products under Development by Companies H2 2017 (Contd..4) H2 2017 Number of Products under Development by Companies H2 2017 (Contd..5) H2 2017 Number of Products under Development by Companies H2 2017 (Contd..6) H2 2017 Number of Products under Development by Universities/Institutes H2 2017 Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 (Contd..1) H2 2017 Products under Development by Companies H2 2017 (Contd..2) H2 2017 Products under Development by Companies H2 2017 (Contd..3) H2 2017 Products under Development by Companies H2 2017 (Contd..4) H2 2017 Products under Development by Companies H2 2017 (Contd..5) H2 2017 Products under Development by Companies H2 2017 (Contd..6) H2 2017 Products under Development by Companies H2 2017 (Contd..7) H2 2017 Products under Development by Companies H2 2017 (Contd..8) H2 2017 Products under Development by Universities/Institutes H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881449/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|